Prognosis of advanced bronchopulmonary cancer

Introduction: Primary bronchopulmonary cancer represents the leading cause of cancer mortality in men worldwide. Objective: To evaluate the prognosis of patients with locally advanced and metastatic non-small cell lung carcinoma (NSCLC) and to determine prognostic factors at these stages. Methods: Retrospective study including 140 cases of locally advanced and metastatic NSCLC diagnosed in our department between 2003 and 2013. Results: The mean age was 61±10 years with a clear male predominance. The cancer was stage IIIA in 14%, IIIB in 27% and IV in 59%. Survival at 6 months and 1 year was 50-74% and 9-25%, respectively. Survival was significantly longer in patients with stage III cancer, a performance status (PS) of 0 to 1, comorbidities, prolonged time to positive diagnosis, short treatment time, and who received specific antitumor therapy. Conclusion: Prognostic factors for advanced NSCLC are PS, stage, comorbidities, time to management, and specific antitumor therapy.

Autorentext

Dr. Kwas Hamida, außerordentlicher Professor für Pneumologie am Universitätskrankenhaus von Gabès, Universität Sfax, Tunesien.